Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 5.77%
As of Tuesday, August 25, Cartesian Therapeutics, Inc.’s RNAC share price has surged by 5.77%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Commentary & Analysis
Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.38%
As of Monday, August 24, Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Michael Rose
Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 7.50%
As of Wednesday, August 19, Cartesian Therapeutics, Inc.’s RNAC share price has surged by 7.50%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 11.25%
As of Wednesday, August 19, Cartesian Therapeutics, Inc.’s RNAC share price has surged by 11.25%, which has investors questioning if this is right time to sell.Omar Beirat
Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 6.22%
As of Monday, August 17, Cartesian Therapeutics, Inc.’s RNAC share price has surged by 6.22%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | RNAC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $275.9 | $289.2 | 30% |
|
| Shares Out (Mil) | 29.9 | 54.1 | 37% |
|
| Institutional Ownership | 28.7% | 93.1% | 12% |
|
| Float (Mil) | 11.5 | 42.2 | 21% |
|
| Beta | 0.56 | 0.94 | 32% |
|
| Avg Daily Volume (000s) | 103 | 451 | 37% |
|
| Price Change (52-week) |
(11.0%) | 59.8% | 36% |
|
| Growth | RNAC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($1.010) | ($2.780) | ($3.810) | |
| Month Ago EPS | ($0.690) | ($3.350) | ($2.680) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.690) | ($3.350) | ($2.680) | |
| Year/Year Chg | (319.6%) | (44.6%) | (18.5%) | |
| Financials | RNAC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($152) | ($43) | 8% |
|
| EPS (TTM) | ($5.610) | ($1.500) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($13) | $2 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $60 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $220 | $190 | 27% |
|
| Valuation | RNAC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RNAC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (42.9%) | (47.8%) | 13% |
|
| ROE | 237.8% | (55.0%) | 98% |
|
| Liabilities to Assets | 139.3% | 29.7% | 98% |
|
| F-Score | 2 | 3 | 7% |
|
Cartesian Therapeutics, Inc. did not pass any screens on 9/3/2026.
